CAJ | 학술논문

【目的】探讨曲妥珠单抗联合不同化疗药物治疗乳腺癌的临床疗效。【方法】收集整理2007年1月至2010年1月期间在本院接受曲妥珠单抗治疗的97例乳腺癌患者的临床资料，其中单用曲妥珠单抗(A组)治疗的30例，曲妥珠单抗联合长春瑞滨方案(B 组)治疗者33例，曲妥珠单抗联合紫杉醇方案(C)治疗者34例。比较分析不同方案的治疗效果、治疗期间的毒副反应及患者生存情况。【结果】B 组治疗乳腺癌患者的总有效为36.36%，疾病控制率为78.78%；C组治疗乳腺癌患者的总有效率为32.35%，疾病控制率为67.65%；两组临床总有效率及疾病控制率均显著高于 A 组，且差异有显著性(P <0.05)；治疗期间曲妥珠单抗联合不同化疗方案治疗乳腺癌患者的耐受性良好，未出现治疗相关性死亡；曲妥珠单抗联合化疗药物治疗后1、2、5年生存率均均显著高于单用曲妥珠单抗(P <0.05)，但 B 组与 C 组之间相比较差异无显著性(P >0.05)。【结论】曲妥珠单抗联合不同化疗药物治疗乳腺癌的临床疗效优于单用曲妥珠单抗，且患者毒副作用均可耐受，值得临床推广应用。
【목적】탐토곡타주단항연합불동화료약물치료유선암적림상료효。【방법】수집정리2007년1월지2010년1월기간재본원접수곡타주단항치료적97례유선암환자적림상자료，기중단용곡타주단항(A조)치료적30례，곡타주단항연합장춘서빈방안(B 조)치료자33례，곡타주단항연합자삼순방안(C)치료자34례。비교분석불동방안적치료효과、치료기간적독부반응급환자생존정황。【결과】B 조치료유선암환자적총유효위36.36%，질병공제솔위78.78%；C조치료유선암환자적총유효솔위32.35%，질병공제솔위67.65%；량조림상총유효솔급질병공제솔균현저고우 A 조，차차이유현저성(P <0.05)；치료기간곡타주단항연합불동화료방안치료유선암환자적내수성량호，미출현치료상관성사망；곡타주단항연합화료약물치료후1、2、5년생존솔균균현저고우단용곡타주단항(P <0.05)，단 B 조여 C 조지간상비교차이무현저성(P >0.05)。【결론】곡타주단항연합불동화료약물치료유선암적림상료효우우단용곡타주단항，차환자독부작용균가내수，치득림상추엄응용。
[Objective]To study the clinical effect of trastuzumab therapy with the combination of chemo-therapy drugs for treatment of breast cancer.[Methods]97 cases of patients with breast cancer undergoing trastuzumab combined with different chemotherapy drugs in our hospital were collected from January 2007 to January 2010,among which 30 cases (Group A)were treated with trastuzumab only,33 cases(Group B)with trastuzumab plus vinorelbine ,and 34 cases (Group C)with trastuzumab combined with paclitaxel .A retro-spective analysis of the effects of different treatment programs was undertaken on therapeutic efficacy,toxic and adverse effects and patient survival situation.[Results]Total effective of Group B for the treatment of pa-tients with breast cancer is 36.36% with its disease control rate 78.78%;Total effective of Group C was 32.35% ,and its disease control rate 67.65%;The total clinical effectives and disease control rates of the two groups were significantly higher than those of Group A,with obvious difference there exits (P <0.05).Dur-ing treatment ,trastuzumab combined with different chemotherapy drugs for breast cancer is well tolerated, and no treatment-related deaths occurred;The survival rate of 1,2 and 5 year period under trastuzumab com-bination therapy is significantly higher than that of trastuzumab alone ,but there was no significant difference between Group B and Group C (P >0.05 )[Conclusion]Combination therapy of trastuzumab with different chemotherapy drugs for treatment of breast cancer is clinically superior to that of trastuzumab alone.The toxic and adverse effects herewith are well tolerated.Thus ,it is worth of clinical application.